炎症性肠病序贯生物治疗的安全性:来自三级转诊中心的结果
该回顾性队列研究纳入1996年至2019年一家三级转诊中心连续暴露于阿达木单抗、英夫利西单抗、乌司奴单抗或维得利珠单抗的1575例炎症性肠病患者,中位随访10年、生物治疗时长71个月。生物暴露后严重感染发生率为3.4/100患者年,恶性肿瘤发生率为1.06/100患者年,风险与生物制剂类型及数量无关。结论认为序贯生物治疗似乎不增加严重感染或恶性肿瘤的总体风险,但更难治的 underlying 疾病似乎增加该风险。
要点
- 序贯使用生物制剂似乎不增加严重感染或恶性肿瘤的总体风险。
- 严重感染与全身激素单药、激素联合生物制剂、女性及既往严重感染相关。
- 恶性肿瘤风险随生物治疗启动时年龄增长而升高。
核心结论
- 炎症性肠病序贯生物治疗似乎不增加严重感染或恶性肿瘤的总体风险,但更 Prev 难治的 underlying 疾病似乎增加该风险。
研究设计与样本
- 回顾性队列研究,在一家三级转诊中心纳入1996年至2019年间连续暴露于阿达木单抗、英夫利西单抗、乌司奴单抗或维得利珠单抗的炎症性肠病患者,共1575例,中位随访10(6-16)年,生物治疗时长71(39-112)个月。
主要发现
- 生物暴露后严重感染发生率为3.4/100患者年。
- 生物暴露后恶性肿瘤发生率为1.06/100患者年。
- 严重感染与全身激素单药治疗相关(HR 2.96,95%CI 1.78-4.93,p<0.0001)。
- 严重感染与全身激素联合生物制剂治疗相关(HR 2.44,95%CI 1.37-4.34,p=0.002)。
- 严重感染与女性(HR 1.25,95%CI 1.04-1.51,p=0.02)及生物治疗前严重感染史(HR 1.42,95%CI 1.03-1.96,p=0.03)相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologicals represent the cornerstone of treatment for moderate-to-severe inflammatory bowel diseases (IBD). Many patients cycle between biologicals when encountering loss of response or adverse events. AIM: To assess the occurrence of serious infections and malignancies with exposure to several (classes of) biologicals. METHODS: We performed a retrospective cohort study in a tertiary referral centre including consecutive IBD patients exposed to adalimumab, infliximab, ustekinumab or vedolizumab between 1996 and 2019. All serious infections and malignancies, as well as potential confounders, were accounted for. RESULTS: In total, 1575 patients were included with a median (interquartile range) follow-up of 10 (6-16) years and a duration of biological therapy of 71 (39-112) months. Incidence rates of serious infections were 3.4 per 100 patients' years (PY) in the post-biological setting. Serious infections after biological exposure were associated with systemic steroids in monotherapy (hazard ratio 2.96 [95% confidence interval 1.78-4.93], p < 0.0001), combination therapy of systemic steroids and a biological (2.44 [1.37-4.34], p = 0.002), female gender (1.25 [1.04-1.51], p = 0.02), and prior serious infections in the pre-biological setting (1.42 [1.03-1.96], p = 0.03). Malignancy rates were 1.06 per 100PY in the post-biological setting and increased with older age at biological initiation (1.04 [1.02-1.05], p < 0.0001). The risk for serious infections or malignancies was independent of type and number of biologicals to which the patient was exposed. CONCLUSION: This study shows that the sequential use of biological therapy in IBD does not seem to convey an overall higher risk of serious infections or malignancies, but that underlying more refractory disease seems to increase this risk.
引用
- Moens A, Sadat Seyed Tabib N, Ballet V, et al. Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral centre. Aliment Pharmacol Ther. 2022. PMID: 35441398. doi:10.1111/apt.16928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。